Mar 30, 2020
ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology
Sep 25, 2019
ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going "Base Line/On Therapy" (BOT) Phase II Clinical Trial
Jul 24, 2019
ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center
Jun 20, 2019
ImaginAb to Present at SNMMI 2019 Annual Meeting
May 16, 2019
ImaginAb Enrolls First Patient in Phase II Clinical Trial at a World-Leading Cancer Center in Los Angeles County
Feb 26, 2019
ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board
Jan 18, 2019
ImaginAb Enrolls First Patient in Phase II Clinical Trial
Jan 03, 2019
ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics
Jan 02, 2019
ImaginAb Announces Strengthening of Board and Executive Leadership Team
Aug 29, 2018
ImaginAb and CPDC Announce Clinical Trial Supply Manufacture and Distribution Agreement for ImaginAb's CD8 Immuno PET Tracer
Jul 09, 2018
ImaginAb Appoints James Allison, Padmanee Sharma and Ramy Ibrahim to Scientific Advisory Board
Jun 22, 2018
ImaginAb Reconstitutes Japanese Subsidiary
May 17, 2018
ImaginAb Reconstitutes Scientific Advisory Board
Oct 09, 2017
ImaginAb Closes $8 million New Funding to Accelerate Clinical Development of CD8 ImmunoPET Agent
Sep 25, 2017
ImaginAb Inc. Announces Strategic Collaboration with Boehringer Ingelheim to Develop New Technology for Monitoring Anti-tumor Activity of the Immune System